For years, CRISPR Therapeutics (CRSP 1.25%) has been the type of stock investors might call a home run swing. The company ...

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ...

With few treatments available for sickle cell disease, encouraging early clinical data for a Fulcrum Therapeutics drug made it one to watch. But another medicine from the same drug class was recently ...

A team of researchers led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) has developed a ...

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts ...

A team of researchers led by Luigi Naldini at the San Raffael Institute for Gene Therapy (SR-Tiget) has developed a new ...

Ex vivo treatment is a long and complex process, but Intellia is attempting to score a historic first approval for an in vivo ...

Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates substantial free ...

Jefferies Global Healthcare Conference 2026 June 3, 2026 9:55 AM EDTCompany ParticipantsSamarth Kulkarni - CEO ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 7.9% in the past three months. One major reason for the weakness ...

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared ...